Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
about
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon.Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistanceAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionClostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventionsThe changing epidemiology of Clostridium difficile infectionsStrain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.Equine hyperimmune serum protects mice against Clostridium difficile spore challengeLack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.In vitro activity of OPT-80 against Clostridium difficile.Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.Clostridium difficile colitis: a review.Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolateClostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen.A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A⁻B⁺ isolates and increase of A⁺B⁺ isolates.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Future novel therapeutic agents for Clostridium difficile infection.Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study.Clostridium difficile-associated diarrhea in adultsIn vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004On Lactococcus lactis UL719 competitivity and nisin (Nisaplin(®)) capacity to inhibit Clostridium difficile in a model of human colon.Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.Antibiotic-associated diarrhoea.Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.Clostridium difficile: recent epidemiologic findings and advances in therapy.Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.New advances in the treatment of Clostridium difficile infection (CDI)Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.DETECTION, RIBOTYPING AND ANTIMICROBIAL RESISTANCE PROPERTIES OF CLOSTRIDIUM DIFFICILE STRAINS ISOLATED FROM THE CASES OF DIARRHEA.Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.Clinical update for the diagnosis and treatment of Clostridium difficile infection.Treatment of refractory and recurrent Clostridium difficile infection.Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients.Immunization strategies for Clostridium difficile infections.Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.
P2860
Q24632558-32386766-85DC-4F58-825C-1F7E4552DEDBQ24632641-88A08294-58AA-4F23-BFC1-DFA4DA7D7073Q28084026-E429432E-01E0-49DB-ACCC-65FD570D340BQ28743438-80BB8956-A9C4-4B51-96CA-17E51E32BACFQ28750385-AFE1D861-48E1-4072-9999-8F35DC54EBDAQ33798369-839D9E05-EC88-40DD-AF01-55EA673608C4Q33856726-BA2D52E8-F83C-4B38-87F6-1FD1FEFE8C7DQ33865434-18664699-03AD-45DF-A7DD-240B35AC1386Q34072892-B38B6BA7-32B2-40F7-BB34-DC757E60345AQ34142125-2E337DDD-A736-426F-85EF-DE5B3816F546Q34234559-947668E5-53AA-4F26-878E-86B597D334CDQ34260389-A4D6498F-6551-407F-BEAE-B2DE65602FA1Q34562315-D42F77FD-B46E-4F74-9E09-D92A8F7D4B82Q34638198-17AC65BF-2453-429B-885B-941DF1C843CFQ34643123-EA154148-95F3-4CA8-9CA7-7F3D7F78859DQ35014457-63E8F905-3422-4A83-B835-D45F3992AC04Q35155775-DFD46895-9407-4B2B-8B43-19E2A826DDB0Q35175136-5B6402B8-185D-4F9E-92FB-91399B58443EQ35208564-24E2AEBF-73A0-4CCA-9045-904BE984615FQ35550741-2B91BB6A-3D14-411E-8240-F818917A4C0EQ35828291-11A3839F-037D-44DE-98C1-04086D8E75BBQ35912682-F62EB380-B9C7-4D7D-80D2-BB6964BDE4F7Q36098158-6EE87225-2CDB-462D-BF47-50F8495B8AA0Q36106735-D53FCA3A-E779-41ED-BC90-83B323B0C3C8Q36446885-2502926D-8392-4417-9B7D-019D3FBCFEDCQ36482832-7D76BFF7-7AEC-4FB0-BC86-BC23F59D46ADQ36792749-9B38D682-EE50-4C8F-9A9B-05BA32304EBFQ36861661-43B52788-0A29-4B0B-A4AB-333D87E1AF18Q36898358-DF7D7B82-0ABA-4B64-B467-1C8A252DE2E4Q37035829-D2C08E0C-C64C-4139-A074-B5B71D92E036Q37052819-69BC8DB4-9940-4B44-AA8D-78D0A298500AQ37274745-C9F8071E-BAD6-499C-B482-CC13FDB264C8Q37439161-4C6D6FE2-063B-4043-BD55-BBD4EB9CE964Q37491761-FFBD9CFB-955E-47BA-B0D7-B060A4CB3A27Q37569179-9D5B3FA7-BC3C-4F6F-B884-CF8BE48C7E31Q37633859-B9E6BBFD-153B-469C-935F-6EF5B06CB64BQ37866629-D623F6C3-B7E7-410B-BFD5-F986D576AB74Q37871901-469729B3-3DAF-4DCC-875B-BDA10C77B6BAQ38006996-8569EF04-A661-4F14-911B-45C08E50AB5BQ38538221-D9BB74F5-3CB3-402F-8663-DFAEF52FE3DE
P2860
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@ast
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@en
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@nl
type
label
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@ast
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@en
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@nl
prefLabel
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@ast
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@en
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@nl
P2093
P2860
P1476
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
@en
P2093
J M García-Lechuz
M Rodríguez-Créixems
P2860
P304
P356
10.1128/AAC.46.6.1647-1650.2002
P407
P50
P577
2002-06-01T00:00:00Z